Pharmaceutical

Janssen seeks EMA authorisation for urothelial cancer treatment

Janssen has filed a marketing authorisation application with the European Medicines Agency for erdafitinib to treat urothelial carcinoma.

Sep 11, 2023 - 20:00
Janssen seeks EMA authorisation for urothelial cancer treatment
Janssen has filed a marketing authorisation application with the European Medicines Agency for erdafitinib to treat urothelial carcinoma.
Read the original article

Tags:

Previous Article

Biosyngen receives FDA approval to start Phase I trial for TCR therapy

Next Article

Alexion and Verge enter AI-powered drug discovery deal

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Leading MD Anderson oncologist disputes junior scientist’s claims in lawsuit over research credit

STAT+: Leading MD Anderson oncologist disputes junior s...

Feb 17, 2024

Amgen acquires Horizon Therapeutics for $27.8bn

Amgen acquires Horizon Therapeutics for $27.8bn

Oct 9, 2023

STAT+: Pharmalittle: Supreme Court halts Purdue bankruptcy plan; what to know about compounded obesity drugs

STAT+: Pharmalittle: Supreme Court halts Purdue bankrup...

Aug 11, 2023